App for monitoring tuberculosis remotely being tested; AtriCure wins IDE for afib device;

@FierceMedDev: ReShape finally reveals pivotal obesity data ahead of FDA review. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Covidien sells drug-coated balloon for $30M to appease regulators as it barrels toward Medtronic merger. Article | Follow @VarunSaxena2

@EmilyWFierce: New medical imaging device with scanner the size of an iPhone uses ultrasound chip to create 3-D images in real time. Story from MIT Technology Review | Follow @EmilyWFierce

> Health app developer emocha partnered with the Baltimore City Health Department to pilot the company's app miDOT, which will allow physicians to monitor tuberculosis patients remotely. Story

> AtriCure ($ATRC), an atrial fibrillation device maker, was granted an investigational device exemption from the FDA for its trial evaluating patients with persistent or long-standing atrial fibrillation. News

> The high costs of implants and new technology worry orthopedic surgeons thinking about the future of patient treatment. Surgeons and hospital administration are often at odds about the importance of costly devices. More

Biotech News

@FierceBiotech: AstraZeneca builds cancer R&D dream house with $150M Definiens buyout, J&J deal. Article | Follow @FierceBiotech

@JohnCFierce: Joined at the hip. RT @bradloncar: Len Schleifer mentioned Viehbacher axing. he's meeting with Weinberg soon, $REGN very committed to $SNY. | Follow @JohnCFierce

@DamianFierce: I've been off Twitter for a minute. Has anyone called for a $REGN breakup yet? | Follow @DamianFierce

@EmilyMFierce: How does HIV hide? One hideout theory may not hold up. Story | Follow @EmilyMFierce

> Astellas sinks deeper roots into Cambridge's hot R&D field with $1.2B discovery pact. Article

> Rand tallies a whopping $44B in biosimilar drug savings. Item

> Novo Nordisk builds blockbuster case with promising PhIII obesity data. Report

Pharma News

@FiercePharma: Top-read on FP Monday: AstraZeneca seals the deal for Almirall's respiratory meds. Article | Follow @FiercePharma

@EricPFierce: ICYMI yesterday: The revamp continues at Takeda, as does its financial struggles. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Report: Orphan drugs to nab 19% of drug sales by 2020--if payers don't balk, that is. Article | Follow @CarlyHFierce

> Which drugs win the script popularity contest? Crestor, Synthroid and Nexium. Story

> Allergan discloses a secret admirer looking to make an offer. Could it be ... Actavis? More

Biotech Research News

> Three-drug combo kills Ewing sarcoma in mice. More

> Potential target for triple-negative breast cancer found. Story

> 3D stomach tissue grown from human stem cells. Item

> Mouse model shows genetics plays role in Ebola severity. Article

> Drug combo causes lung cancer cells to self-destruct. More

Pharma Manufacturing News

> GSK gets go-ahead for expansion at plant in Scotland. Item

> Forest recalls another 90,000-plus bottles of Bystolic. Report

> Chinese company takes over Boehringer U.S. plant as German drugmaker expands in China. More

> Chairman says Wockhardt has no plans to sell. Story

> Novartis cuts more jobs at U.S. consumer plant ahead of handing it off to GSK. Article

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.